{"id":251338,"date":"2024-05-06T00:00:00","date_gmt":"2024-05-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidid0046-biopharma-human-papilloma-virus-vaccine-epidemiology-2\/"},"modified":"2026-05-08T11:27:06","modified_gmt":"2026-05-08T11:27:06","slug":"epidid0046-biopharma-human-papilloma-virus-vaccine-epidemiology-mature-markets-data","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidid0046-biopharma-human-papilloma-virus-vaccine-epidemiology-mature-markets-data\/","title":{"rendered":"Human Papilloma Virus Vaccine &#8211; Epidemiology &#8211; Mature Markets Data"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of the human papillomavirus (<abbr title=\"human papillomavirus\">HPV<\/abbr>) vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the eligible population recommended to receive the <abbr title=\"human papillomavirus\">HPV<\/abbr> vaccine for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"human papillomavirus\">HPV<\/abbr> vaccine forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of the <abbr title=\"human papillomavirus\">HPV<\/abbr> vaccine-eligible population over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology forecasts the following <abbr title=\"human papillomavirus\">HPV<\/abbr> vaccine patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>The population eligible for the <abbr title=\"human papillomavirus\">HPV<\/abbr> vaccine.<\/li>\n<li>The population newly eligible for the <abbr title=\"human papillomavirus\">HPV<\/abbr> vaccine.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251338","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251338\/revisions"}],"predecessor-version":[{"id":305198,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251338\/revisions\/305198"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}